Articles from Leveragen

Leveragen, a Boston-based biotechnology company developing next-generation in vivo platforms for antibody discovery, today announced a collaboration agreement with Daiichi Sankyo (TSE: 4568) to support research efforts in advanced biologics.

Leveragen, Inc., a Boston-based biotechnology company advancing next-generation in vivo antibody discovery, announced today the issuance of a patent in Japan covering core innovations underlying its Singularity Platform, the proprietary system that supports the company’s Singularity Suite of genetically engineered mouse models for single-domain antibody (sdAb) discovery. The patent strengthens Leveragen’s growing global intellectual property estate supporting long-term partnerships with pharmaceutical and biotechnology companies worldwide.

Leveragen, a Boston-based biotechnology company pioneering next-generation in vivo antibody discovery platforms, announced today a strategic collaboration with Propeller Bio, a newly launched biotechnology company focused on antibody and protein-based therapeutics. As part of the partnership, Propeller Bio will support the continued development of Leveragen’s antibody discovery platforms through a strategic investment. In turn, Propeller will collaborate closely with Leveragen and gain access to Leveragen’s full suite of proprietary antibody mouse models, including the Singularity Sapiens Mouse, the industry-leading fully human single-domain antibody discovery platform.

Dapu Biotechnology (DPBIO), an industry leader in droplet microfluidic technology, and Leveragen, Inc., a Boston-based biotech developing advanced genetic models for antibody discovery, have announced a strategic partnership to accelerate innovations in antibody drug development.